HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors
HONG KONG, June 21, 2021 /PRNewswire/ -- HUTCHMED (China) Limited ("HUTCHMED
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference
NEW YORK, June 6, 2016 /PRNewswire/ -- Deutsche Bank today announced the lineup for itsJune 9th and 10th Depositary Receipts Virtual Investor Conference ("dbVIC"), featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Represe...
Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016
HONG KONG, June 6, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based inChina, and globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products, today announced that Chief Execu...
